Tidutamab
Modify Date: 2025-09-21 10:32:36
Tidutamab structure
|
Common Name | Tidutamab | ||
|---|---|---|---|---|
| CAS Number | 2148354-90-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TidutamabTidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC)[1]. |
| Name | Tidutamab |
|---|
| Description | Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Tidutamab (XmAb-18087; 0-100000 ng/mL)与人 SSTR2+ CHO 细胞结合，ED50 值为 2.2 μg/mL，并介导 T 细胞杀伤 SSTR2+ 靶细胞[1]。 |
| In Vivo | Tidutamab (XmAb-18087; 3 mg/kg; i.p.; 单次注射) 在 NSG 小鼠中刺激人 T 细胞杀伤 SSTR2+ A549 肺癌肿瘤[1]。 Animal Model: NSG mice[1] Dosage: 3 mg/kg Administration: Intraperitoneal injection; single dose Result: lnduced anti-tumor activity in human PBMC-engrafted NSG mice. |
| References |
| No Any Chemical & Physical Properties |